Reporter brief

Trial registry update: COMPLETED. Results are posted in the registry; assessment pending.

Assessment pending; this report does not establish a change in evidence.

• —No actual findings are reported, so no conclusions about metformin's efficacy can be drawn from this text.
• —The study's rationale—that insulin resistance and inflammation drive frailty—is stated as an investigator hypothesis, not an established fact.
• —Without results, it cannot be determined whether the intervention actually prevents frailty, ameliorates progression, or has any clinical effect.

Rct; Human.

High-risk older adults; mean age 71-72 years; 48% female (68/141 at baseline); 93% White, 4% African American, 2% Other; 35% Hispanic or Latino

Design

Rct

Sample

125

Journal

The University of Texas Health Science Center at San Antonio

Published

Oct 15, 2026

Primary outcome - Metformin: 0.0289 (SE 0.0049); Placebo: 0.0164 (SE 0.0058). Secondary outcome - Metformin: -0.0002 (SE 0.0002); Placebo: 0.0002 (SE 0.0002)

• —Assessment: Superseded.
• —Only the source material recorded on this evidence page was assessed.

Not recorded.

See the Metformin timeline and recorded assessment for prior evidence.